Document:

EXHIBIT 4.1

 THIS NOTE  HAS NOT  BEEN REGISTERED  UNDER THE  SECURITIES ACT  OF 1933,  AS
 AMENDED (THE "SECURITIES ACT"), OR ANY  STATE SECURITIES LAW AND MAY NOT  BE
 SOLD, TRANSFERRED  OR  OTHERWISE DISPOSED  OF  UNLESS REGISTERED  UNDER  THE
 SECURITIES ACT AND  UNDER APPLICABLE STATE  SECURITIES LAWS  OR THE  COMPANY
 SHALL HAVE RECEIVED  AN OPINION OF  COUNSEL THAT REGISTRATION  OF THIS  NOTE
 UNDER THE  SECURITIES  ACT AND  UNDER  THE PROVISIONS  OF  APPLICABLE  STATE
 SECURITIES LAWS IS NOT REQUIRED.

 THIS NOTE  SUBJECT TO  CERTAIN RESTRICTIONS  ON  TRANSFER CONTAINED  IN  THE
 PURCHASE AGREEMENT (AS DEFINED BELOW). A COPY OF SUCH PURCHASE AGREEMENT AND
 ALL APPLICABLE AMENDMENTS THERETO  WILL BE FURNISHED BY  THE COMPANY TO  THE
 HOLDER HEREOF WITHOUT  CHARGE UPON  WRITTEN REQUEST  TO THE  COMPANY AT  ITS
 PRINCIPAL PLACE OF BUSINESS OR REGISTERED OFFICE.

 THIS  NOTE  AND  THE  INDEBTEDNESS  OF  THE  COMPANY  EVIDENCED  HEREBY  ARE
 SUBORDINATE TO THE PAYMENT OF CERTAIN OTHER INDEBTEDNESS OF THE COMPANY,  AS
 MORE PARTICULARLY DESCRIBED HEREIN.

                        CARRINGTON LABORATORIES, INC.

                      6.0% SUBORDINATED PROMISSORY NOTE

 U.S. $[___________]                                     IRVING, TEXAS
                                                         NO.: PN-2005-
                                                         November 18, 2005

      FOR VALUE RECEIVED, the undersigned, Carrington Laboratories, Inc., a
 Texas corporation (the "Company"), hereby promises to pay to the order of
 [_______________] or any future holder of this subordinated promissory note
 (the "Payee"), at the address of the Payee set forth herein, or at such
 other place as the Payee may designate in writing to the Company, the
 principal sum of up to [____________] Dollars (U.S. $[____________]), or
 such other amount as may be outstanding hereunder, together with all accrued
 but unpaid interest, in such coin or currency of the United States of
 America as at the time shall be legal tender for the payment of public
 and private debts and in immediately available funds, as provided herein.

      This 6.0% Subordinated Promissory Note (this "Note") is one of a series
 of 6.0% Subordinated Promissory Notes issued by the Company in the aggregate
 amount of $5,000,000 pursuant to the terms and provisions of that certain
 Promissory Note and Warrant Purchase Agreement dated as of the date hereof
 (the "Purchase Agreement") among the Company, the Payee, and the other
 purchasers party thereto.

      1. Principal And Interest Payments.

           (a) The Company shall repay in full the entire principal balance
 then outstanding under this Note on the first to occur (the "Maturity Date")
 of: (i) the Payment Date, or (ii) the acceleration of the unpaid principal
 balance of this Note pursuant to the provisions hereof.  As used herein, (a)
 "Payment Date" means the first to occur of: (i) November 18, 2009, or (ii)
 the tenth Business Day (defined below) after the full exercise by Payee of
 its Series A Warrant (as defined in the Purchase Agreement) issued to Payee
 on the date hereof; and (b) "Business Day" means any day except Saturday,
 Sunday and any day which shall be a federal legal holiday or a day on which
 banking institutions in the State of Texas are authorized or required by law
 or other governmental action to close

           (b) Interest on the outstanding principal balance of this Note
 shall accrue at a rate of six percent (6%) per annum, compounded quarterly.
 Interest on the outstanding principal balance of this Note shall be computed
 on the basis of the actual number of days elapsed (including the first day,
 but excluding the last) and a year of three hundred sixty (360) days and
 shall be payable quarterly within ten (10) calendar days from the end of
 each calendar quarter.

           (c) At the Company's sole option, the Company may prepay, in whole
 or in part, the outstanding principal balance of this Note, plus all accrued
 and unpaid interest on the amount so prepaid, at any time and from time to
 time, in each case without premium or penalty.

      2. Non-Business Days. Whenever any payment to be made under this Note
 shall be due on a day that is not a Business Day, such payment shall be due
 on the next succeeding Business Day and such next succeeding day shall be
 included in the calculation of the amount of accrued interest payable on
 such date.

      3. Events Of Default. The occurrence of any of the following events
 shall be an "Event of Default" under this Note:

           (a) the Company fails to pay any principal or interest under this
 Note when due and payable and such failure is not remedied within ten (10)
 Business Days thereafter; or

           (b) the Company (i) fails to duly pay any indebtedness in excess
 of $2,000,000 constituting principal or interest owed by it with respect
 to borrowed money or money otherwise owed under any note, bond, or similar
 instrument, or (ii) otherwise breaches or defaults in the performance of any
 agreement or instrument by which any such indebtedness is issued, evidenced,
 governed, or secured, and, in each case, (1) any such failure, breach or
 default results in the acceleration of such indebtedness, and (2) such
 indebtedness has not been discharged in full or such acceleration has not
 been stayed, rescinded or annulled within five (5) Business Days of such
 acceleration; or

           (c) the Company shall (i) apply for or consent to the appointment
 of, or the taking of possession by, a receiver, custodian, trustee or
 liquidator of itself or of all or a substantial part of its property or
 assets, (ii) make a general assignment for the benefit of its creditors,
 (iii) commence a voluntary case under the United States Bankruptcy Code
 (the "Bankruptcy Code") or under the comparable laws of any jurisdiction
 (foreign or domestic), (iv) file a petition seeking to take advantage of
 any bankruptcy, insolvency, moratorium, reorganization or other similar law
 affecting the enforcement of creditors' rights generally, (v) acquiesce in
 writing to any petition filed against it in an involuntary case under the
 Bankruptcy Code or under the comparable laws of any jurisdiction (foreign or
 domestic), or (vi) take any action under the laws of any jurisdiction
 (foreign or domestic) analogous to any of the foregoing; or

           (d) a proceeding or case shall be commenced in respect of the
 Company or any of its subsidiaries without its application or consent,
 in any court of competent jurisdiction, seeking (i) the liquidation,
 reorganization, moratorium, dissolution, winding up, or composition or
 readjustment of its debts, (ii) the appointment of a trustee, receiver,
 custodian, liquidator or the like of it or of all or any substantial part of
 its assets or (iii) similar relief in respect of it under any law providing
 for the relief of debtors, and such proceeding or case described in clause
 (i), (ii) or (iii) shall continue undismissed, or unstayed and in effect,
 for a period of sixty (60) consecutive days or any order for relief shall
 be entered in an involuntary case under the Bankruptcy Code or under the
 comparable laws of any jurisdiction (foreign or domestic) against the
 Company or any of its subsidiaries or action under the laws of any
 jurisdiction (foreign or domestic) analogous to any of the foregoing shall
 be taken with respect to the Company or any of its subsidiaries and shall
 continue undismissed, or unstayed and in effect for a period of sixty (60)
 consecutive days; or

           (e) the suspension from listing or the failure of the Company's
 common stock, $0.01 par value per share, to be listed on any of the OTC
 Bulletin Board, American Stock Exchange, Nasdaq National Market or Nasdaq
 SmallCap Market for a period of five (5) consecutive trading days.

      4. Remedies Upon An Event Of Default.  If an Event of Default shall
 have occurred and shall be continuing, the Payee of this Note may at any
 time at its option, declare the entire unpaid principal balance of this
 Note, together with all interest accrued hereon, due and payable, and
 thereupon, the same shall be accelerated and so due and payable.  This
 remedy shall not be exclusive of any other remedy referred to herein or
 now or hereafter available at law, in equity, by statute or otherwise.

      5. Replacement.  Upon receipt of a duly executed, notarized and
 unsecured written statement from the Payee with respect to the loss, theft
 or destruction of this Note (or any replacement hereof) and upon receipt of
 a written agreement of indemnification reasonably acceptable to the Company
 signed by the Payee (or holder at the time thereof) or, in the case of a
 mutilation of this Note, upon surrender and cancellation of such Note, the
 Company shall issue a new Note, of like tenor and amount, in lieu of such
 lost, stolen, destroyed or mutilated Note.

      6. Parties In Interest, Transferability.  This Note shall be binding
 upon the Company and its successors and permitted assigns and the terms
 hereof shall inure to the benefit of the Payee and its successors and
 assigns. This Note may be transferred or sold, subject to the provisions of
 Section 14 of this Note or as otherwise provided in the Purchase Agreement,
 or pledged, hypothecated or otherwise granted as security by the Payee.

      7. Amendments.  This Note may not be modified or amended in any manner
 except in writing executed by the Company and the Payee.

      8. Notices. Any notice, demand, request, waiver or other communication
 required or permitted to be given hereunder shall be in writing and shall
 be effective (a) upon hand delivery by telecopy or facsimile at the address
 or number designated below (if delivered on a Business Day during normal
 business hours where such notice is to be received), or the first Business
 Day following such delivery (if delivered other than on a Business Day
 during normal business hours where such notice is to be received) or (b)
 on the second Business Day following the date of mailing by express courier
 service, fully prepaid, addressed to such address, or upon actual receipt
 of such mailing, whichever shall first occur. The Company will give written
 notice to the Payee at least twenty (20) days prior to the date on which
 dissolution, liquidation or winding-up will take place and in no event shall
 such notice be provided to the Payee prior to such information being made
 known to the public. Notices to the Payee shall be made to the address set
 forth in the Purchase Agreement. Notices to the Company shall be made to the
 following:

 Address of the Company:  Carrington Laboratories, Inc.
                          2001 Walnut Hill Lane
                          Irving, Texas 75038
                          Attention: Chief Financial Officer
                          Tel. No.: (972) 518-1300
                          Fax No.: (972) 518-1020

         with a copy to:  Patterson Belknap Webb & Tyler LLP
                          1133 Avenue of the Americas
                          New York, New York 10036
                          Attention:  Peter J. Schaeffer
                          Tel. No.: (212) 336-2313
                          Fax No.: (212) 336-2222

      9. Governing Law. This Note shall be governed by and construed in
 accordance with the internal laws of the State of Texas, without giving
 effect to the choice of law provisions. This Note shall not be interpreted
 or construed with any presumption against the party causing this Note to be
 drafted.

      10. Headings. Article and section headings in this Note are included
 herein for purposes of convenience of reference only and shall not
 constitute a part of this Note for any other purpose.

      11. Remedies & Characterizations. The remedies provided in this Note
 shall be cumulative and in addition to all other remedies available under
 this Note, at law or in equity (including, without limitation, a decree of
 specific performance and/or other injunctive relief), no remedy contained
 herein shall be deemed a waiver of compliance with the provisions giving
 rise to such remedy and nothing herein shall limit a Payee's right to pursue
 actual damages for any failure by the Company to comply with the terms of
 this Note.

      12. Failure or Indulgence Not Waiver.  No failure or delay on the part
 of the Payee in the exercise of any power, right or privilege hereunder
 shall operate as a waiver thereof, nor shall any single or partial exercise
 of any such power, right or privilege preclude other or further exercise
 thereof or of any other right, power or privilege.

      13. Enforcement Expenses. The Company agrees to pay all reasonable
 costs and expenses of enforcement of this Note, including, without
 limitation, reasonable attorneys' fees and expenses.

      14. Compliance With Securities Laws. The Payee of this Note
 acknowledges that this Note is being acquired solely for the Payee's own
 account and not as a nominee for any other party, and for investment, and
 that the Payee shall not offer, sell or otherwise dispose of this Note other
 than in compliance with the laws of the United States of America and the
 rules of the Securities and Exchange Commission.  This Note and any Note
 issued in substitution or replacement therefore shall be stamped or
 imprinted with a legend in substantially the following form:

                "THIS  NOTE  HAS  NOT  BEEN  REGISTERED  UNDER  THE
                SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES
                ACT"), OR ANY STATE SECURITIES  LAW AND MAY NOT  BE
                SOLD, TRANSFERRED OR  OTHERWISE DISPOSED OF  UNLESS
                REGISTERED  UNDER  THE  SECURITIES  ACT  AND  UNDER
                APPLICABLE STATE  SECURITIES  LAWS OR  THE  COMPANY
                SHALL HAVE  RECEIVED  AN OPINION  OF  COUNSEL  THAT
                REGISTRATION OF THIS NOTE UNDER THE SECURITIES  ACT
                AND  UNDER  THE  PROVISIONS  OF  APPLICABLE   STATE
                SECURITIES LAWS IS NOT REQUIRED."

      15. Severability. The provisions of this Note are severable, and if any
 provision shall be held invalid or unenforceable in whole or in part in any
 jurisdiction, then such invalidity or unenforceability shall not in any
 manner affect such provision in any other jurisdiction or any other
 provision of this Note in any jurisdiction.

      16. Consent To Jurisdiction. Each of the Company and the Payee, by its
 acceptance hereof, (i) hereby irrevocably submits to the jurisdiction of the
 United States District Court sitting in the Northern District of Texas and
 the courts of the State of Texas located in Dallas county for the purposes
 of any suit, action or proceeding arising out of or relating to this Note
 and (ii) hereby waives, and agrees not to assert in any such suit, action or
 proceeding, any claim that it is not personally subject to the jurisdiction
 of such court, that the suit, action or proceeding is brought in an
 inconvenient forum or that the venue of the suit, action or proceeding
 is improper.  Each of the Company and the Payee consents to process being
 served in any such suit, action or proceeding by mailing a copy thereof to
 such party at the address set forth in Section 8 hereof and agrees that such
 service shall constitute good and sufficient service of process and notice
 thereof. Nothing in this Section 16 shall affect or limit any right to serve
 process in any other manner permitted by law.

      17. Waivers.

           (a) Except as otherwise specifically provided herein, the Company
 hereby expressly, irrevocably and unconditionally waives presentment,
 demand, notice of nonpayment, protest and all other demands and notices in
 connection with the delivery, acceptance, performance and enforcement of
 this Note.

           (b) EACH OF THE COMPANY AND THE PAYEE, BY ITS ACCEPTANCE HEREOF,
 HEREBY ACKNOWLEDGES THAT THE TRANSACTION OF WHICH THIS NOTE IS A PART IS A
 "QUALIFIED COMMERCIAL LOAN", AS DEFINED IN CHAPTER 306 OF THE TEXAS FINANCE
 CODE, AS AMENDED (THE "TEXAS FINANCE CODE").

      18. Limitation on Interest.  The Company and Payee, by its acceptance
 hereof, intend to contract in strict compliance with applicable usury law
 from time to time in effect.  In furtherance thereof such persons stipulate
 and agree that none of the terms and provisions contained in this Note, the
 Purchase Agreement, or any other documents or agreements executed in
 connection with the transactions contemplated hereunder or thereunder
 (collectively, the "Transaction Documents") shall ever be construed to
 create a contract to pay, for the use, forbearance or detention of money,
 interest in excess of the maximum amount of interest permitted to be charged
 by applicable law from time to time in effect.  Neither the Company nor any
 present or future guarantors, endorsers, or other persons hereafter becoming
 liable for payment of any obligation under any Transaction Document shall
 ever be liable for unearned interest thereon or shall ever be required to
 pay interest thereon in excess of the maximum amount that may be lawfully
 contracted for, charged, or received under applicable law from time to time
 in effect, and the provisions of this section shall control over all other
 provisions of the Transaction Documents that may be in conflict or apparent
 conflict herewith.  Payee expressly disavows any intention to contract for,
 charge, or collect excessive unearned interest or finance charges in the
 event the maturity of any obligation under any Transaction Document is
 accelerated.  If (a) the maturity of any obligation under any Transaction
 Document is accelerated for any reason, (b) any such obligation is prepaid
 and as a result any amounts held to constitute interest are determined to be
 in excess of the legal maximum, or (c) Payee or any other holder of any or
 all of such obligations shall otherwise collect moneys that are determined
 to constitute interest that would otherwise increase the interest on any or
 all of such obligation to an amount in excess of that permitted to be
 charged by applicable law then in effect, then all sums determined to
 constitute interest in excess of such legal limit shall, without penalty,
 be promptly applied to reduce the then outstanding principal of the related
 obligation or, at Payee's or such holder's option, promptly returned to
 the Company or the other payor thereof upon such determination.  In
 determining whether or not the interest paid or payable, under any specific
 circumstance, exceeds the maximum amount permitted under applicable law,
 Payee and the Company (and any other payors thereof) shall to the greatest
 extent permitted under applicable law, (i) characterize any non-principal
 payment as an expense, fee or premium rather than as interest, (ii) exclude
 voluntary prepayments and the effects thereof, and (iii) amortize, prorate,
 allocate, and spread the total amount of interest throughout the entire
 contemplated term of the instruments evidencing the applicable obligation in
 accordance with the amounts outstanding from time to time thereunder and the
 maximum legal rate of interest from time to time in effect under applicable
 law in order to lawfully contract for, charge, or receive the maximum amount
 of interest permitted under applicable law.  In the event applicable law
 provides for an interest ceiling under Chapter 303 of the Texas Finance
 Code, for that day, the ceiling shall be the "weekly ceiling" as defined in
 the Texas Finance Code, provided that if any applicable law permits greater
 interest, the law permitting the greatest interest shall apply.  As used in
 this section the term "applicable law" means the laws of the State of Texas
 or the laws of the United States of America, whichever laws allow the
 greater interest, as such laws now exist or may be changed or amended or
 come into effect in the future.

      19. Acknowledgment of Security Interest and Subordination. To the
 extent and in the manner provided herein, the Company covenants and agrees,
 and the Payee by accepting this Note agrees, as follows:

           (a) This Note and the payment and enforcement hereof are expressly
 and in all respects, subordinate and junior and inferior to the Senior
 Indebtedness and the payment and enforcement thereof.  As used herein,
 "Senior Indebtedness" of the Company means all liabilities, indebtedness
 and other obligations of the Company arising under the Comerica Credit
 Documents, the Bancredito Indebtedness and any other indebtedness that,
 by its terms, is senior in rights of payment to this Note, whether now
 existing or hereafter arising, including without limitation any renewals,
 modifications or increases thereof; and "Comerica Credit Documents" means
 the Credit Agreement between Company and Comerica Bank, dated September 1,
 2002, as amended from time to time (the "Comerica Credit Agreement"), and
 all other agreements from time to time executed by Company and evidencing or
 securing any liabilities or other obligations of Company to Comerica Bank,
 whether relating to the Comerica Credit Agreement, or otherwise during the
 term of the that Subordination Agreement between Comerica Bank and the
 Payee; and "Bancredito Indebtedness" means  the Bancredito Note dated
 March 2003 and the Bancredito Note dated September 2004 (collectively, the
 "Bancredito Notes" and, together with the Conmerica Credit Documents, the
 "Credit Documents").

           (b) Upon any payment or distribution of the assets of the Company
 upon a total or partial liquidation, dissolution or winding up of the
 Company or in a bankruptcy, reorganization, insolvency, receivership or
 similar proceeding relating to the Company or its property (each such event,
 if any, herein sometimes referred to as a "Proceeding"):

                (i) holders of Senior Indebtedness of the Company shall be
      entitled to receive payment in full in cash of such Senior Indebtedness
      before the Payee is entitled to receive any payment of principal of, or
      premium, if any, or interest on this Note; and

                (ii) until the Senior Indebtedness of the Company (and all
      debt securities issued in replacement of or exchange for such Senior
      Indebtedness) is paid in full in cash, any distribution made by or on
      behalf of the Company to which the Payee would be entitled but for this
      paragraph shall be made to holders of Senior Indebtedness of the
      Company as their interests may appear.

      For purposes of this paragraph "paid in full" or "payment in full", as
 used with respect to Senior Indebtedness of the Company, means the receipt
 of cash in payment of the principal amount of such Senior Indebtedness and
 premium, if any, on and interest thereon (including any interest thereon
 accruing after the commencement of any Proceeding) to the date of such
 payment.

           (c) Notwithstanding anything to the contrary in this Note, prior
 to the Subordination Termination Date, the Payee shall not accept, receive
 or collect (by set-off or other manner) any payment or distribution on
 account of, or ask for, demand or accelerate, directly or indirectly, this
 Note, and the Company shall not make any such payment; except that so long
 as (i) no "Default" or "Event of Default" (as such terms are defined in any
 of the Credit Documents) has occurred and is continuing under such Credit
 Documents, and (ii) no such Default or Event of Default will occur as a
 result of such payment, the Company may make, in accordance with the terms
 of this Note, and the Payee shall be entitled to accept, scheduled payments
 of principal and interest to the Payee.  As used herein, "Subordination
 Termination Date" means the date after the date hereof on which all Senior
 Indebtedness has been paid in cash and satisfied in full and the lenders
 under the Credit Documents have no outstanding commitment (whether or not
 conditioned on the satisfaction of any condition precedent) to lend money or
 otherwise extend credit to the Company under the Credit Documents.

           (d) If a payment or distribution is made to the Payee that because
 of this paragraph should not have been made to the Payee, the Payee shall
 hold it in trust for holders of Senior Indebtedness of the Company and pay
 it over to them as their interests may appear.  As intended beneficiaries
 of the subordination provisions of this Note, any holder of any Senior
 Indebtedness can enforce such provisions directly, in its own name, against
 Payee.

           (e) Prior to the Subordination Termination Date, the Payee shall
 not accelerate or collect or attempt to collect any part of this Note -
 whether through the commencement or joinder of an action or proceeding
 (judicial or otherwise) or a Proceeding, the enforcement of any rights
 against any property of the Company (including any such enforcement by
 foreclosure, repossession or sequestration proceedings), or otherwise -
 without the prior written consent of the holders of the Senior Indebtedness.

           (f) No payment or distribution to the holders of Senior
 Indebtedness pursuant to the provisions of this Note shall entitle the
 Payee to exercise any rights of subrogation in respect thereof prior to the
 Subordination Termination Date, and until such time the Payee shall not have
 any right of subrogation to such holders of Senior Indebtedness on account
 of this Note.  After the Subordination Termination Date, and provided that
 no payments received by the holders of Senior Indebtedness are voidable or
 must otherwise be returned, the Payee shall be subrogated to the rights of
 such holders of Senior Indebtedness to receive distributions applicable to
 Senior Indebtedness to the extent that distributions otherwise payable to
 the Payee have been applied to the payment of the Senior Indebtedness.

           (g) In the event of any conflict between the terms of this Note
 and any written subordination agreement between Payee and a holder of any
 Senior Indebtedness, the terms of such written subordination agreement will
 control.

 THIS NOTE, THE PURCHASE AGREEMENT, AND  THE OTHER TRANSACTION DOCUMENTS  (AS
 DEFINED IN THE PURCHAE AGREEMENT) REPRESENT THE FINAL AGREEMENT BETWEEN  THE
 PARTIES AND MAY NOT BE CONTRADICTED  BY EVIDENCE OF PRIOR,  CONTEMPORANEOUS,
 OR SUBSEQUENT ORAL AGREEMENTS OF THE  PARTIES.  THERE ARE NO UNWRITTEN  ORAL
 AGREEMENTS BETWEEN THE PARTIES.

<PAGE>

      IN WITNESS WHEREOF, the Company has executed and delivered this
 Promissory Note as of the date first written above.

                                    CARRINGTON LABORATORIES, INC.

                                    By:
                                           ----------------------
                                    Name:
                                           ----------------------
                                    Title:
                                           ----------------------EXHIBIT 4.2

 THIS WARRANT AND  THE COMMON STOCK  ISSUABLE UPON EXERCISE  OF THIS  WARRANT
 HAVE NOT BEEN REGISTERED UNDER  THE SECURITIES ACT OF 1933, AS AMENDED  (THE
 "SECURITIES ACT"),  OR  ANY  STATE  SECURITIES LAW  AND  MAY  NOT  BE  SOLD,
 TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE  SECURITIES
 ACT AND UNDER  APPLICABLE STATE SECURITIES  LAWS OR THE  COMPANY SHALL  HAVE
 RECEIVED AN OPINION OF  COUNSEL THAT REGISTRATION  OF SUCH SECURITIES  UNDER
 THE SECURITIES ACT AND UNDER THE  PROVISIONS OF APPLICABLE STATE  SECURITIES
 LAWS IS NOT REQUIRED.

 THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT ARE
 SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER  CONTAINED IN A PROMISSORY  NOTE
 AND WARRANT  PURCHASE AGREEMENT  AMONG THE  COMPANY  AND THE  PARTIES  NAMED
 THEREIN ON  ITS SCHEDULE  1. A  COPY OF  SUCH AGREEMENT  AND ALL  APPLICABLE
 AMENDMENTS THERETO WILL  BE FURNISHED BY  THE COMPANY TO  THE HOLDER  HEREOF
 WITHOUT CHARGE UPON WRITTEN REQUEST TO THE COMPANY AT ITS PRINCIPAL PLACE OF
 BUSINESS OR REGISTERED OFFICE.

                    SERIES A COMMON STOCK PURCHASE WARRANT

                        CARRINGTON LABORATORIES, INC.

 Number of Warrant Shares:                          Warrant No.:CSW-A-_____

      THIS SERIES A COMMON STOCK PURCHASE WARRANT (the "Warrant") certifies
 that, for value received, [_________________](the "Holder"), is entitled,
 upon the terms and subject to the limitations on exercise and the conditions
 hereinafter set forth, at any time on or after the date hereof (the "Initial
 Exercise Date") and on or prior to the close of business on the fourth
 anniversary of the Initial Exercise Date (the "Termination Date") but not
 thereafter, to subscribe for and purchase from Carrington Laboratories,
 Inc., a Texas corporation (the "Company"), up to the number of warrant
 shares set forth above (the "Warrant Shares") of Common Stock, par value
 $.01 per share, of the Company (the "Common Stock"). The purchase price of
 one share of Common Stock under this Warrant shall be equal to the Exercise
 Price, as defined in Section 2(b).

      Section 1. Definitions.  Capitalized terms used and not otherwise
 defined herein shall have the meanings set forth in that certain Promissory
 Note and Warrant Purchase Agreement (the "Purchase Agreement"), dated as of
 November 18, 2005, among the Company and the parties named therein on its
 Schedule 1.

      Section 2. Exercise.

           (a) Exercise of Warrant.

                (i)  Exercise of the purchase rights represented by this
 Warrant may be made, in whole or in part, at any time or times on or after
 the Initial Exercise Date and on or before the Termination Date by delivery
 to the Company at its principal office of a duly executed facsimile copy of
 the Notice of Exercise Form annexed hereto (or such other office or agency
 of the Company as it may designate by notice in writing to the registered
 Holder at the address of such Holder appearing on the books of the Company);
 provided, however, within five Trading Days (as defined below) of the date
 said Notice of Exercise is delivered to the Company, the Holder shall have
 surrendered this Warrant to the Company and the Company shall have received
 payment of the aggregate Exercise Price of the shares thereby purchased by
 wire transfer or cashier's check drawn on a United States bank.  "Trading
 Day" means any day on which the primary market on which shares of Common
 Stock are listed or quoted is open for trading.

                (ii)  In the event that the Closing Price (defined
 below) shall be greater than or equal to $10.00 per share for twenty (20)
 consecutive Trading Days (the "Acceleration Period"), the Termination Date
 of this Warrant shall be accelerated to the later to occur of (i) the tenth
 Business Day following the date on which the Holder receives written notice
 of such event from the Company and (ii) five (5) calendar days after the
 Company gives the Holder written notice of such event triggering the
 Acceleration Period.

           (b) Exercise Price.  The exercise price per share of the Common
 Stock under this Warrant shall be $5.00, which equals the greater of (i)
 the closing bid price for shares of the Common Stock on the Nasdaq National
 Market (the "Closing Price" or in the case in the future the last sale price
 on the primary Trading Market for the Common Stock) for the Trading Day
 immediately preceding the execution and delivery of the Purchase Agreement
 as reported by Bloomberg Financial L.P. plus $0.75, (ii) the Market Price
 (defined below) for the Trading Day immediately preceding the execution and
 delivery of the Purchase Agreement plus $0.75 and (iii) $5.00, subject to
 adjustment hereunder (the "Exercise Price").

           "Market Price" means, for any date, the price determined by the
 first of the following clauses that applies: (a) if the Common Stock is
 then listed or quoted on a the Nasdaq National Market, the New York Stock
 Exchange or the American Stock Exchange (each, a "Trading Market"), the
 daily volume weighted average price of the Common Stock for such date (or
 the nearest preceding date) on the Trading Market on which the Common Stock
 is then listed or quoted as reported by Bloomberg Financial L.P. (based on a
 Trading Day from 9:30 a.m. Eastern Time to 4:02 p.m. Eastern Time); (b) if
 the Common Stock is not then listed or quoted on a Trading Market and if
 prices for the Common Stock are then quoted on the OTC Bulletin Board, the
 volume weighted average price of the Common Stock for such date (or the
 nearest preceding date) on the OTC Bulletin Board; (c) if the Common Stock
 is not then listed or quoted on the OTC Bulletin Board and if prices for the
 Common Stock are then reported in the "Pink Sheets" published by the Pink
 Sheets, LLC (or a similar organization or agency succeeding to its functions
 of reporting prices), the most recent bid price per share of the Common
 Stock so reported; or (d) in all other cases, the fair market value of a
 share of Common Stock as determined by an independent appraiser selected in
 good faith by the Holder and reasonably acceptable to the Company.

           (c) Mechanics of Exercise.

                (i)  Authorization of Warrant Shares.  The Company covenants
 that all Warrant Shares which may be issued upon the exercise of the
 purchase rights represented by this Warrant will, upon exercise of the
 purchase rights represented by this Warrant, be duly authorized, validly
 issued, fully paid and nonassessable.

                (ii)  Delivery of Certificates Upon Exercise.  Certificates
 for shares purchased hereunder shall be transmitted by the transfer agent
 of the Company to the Holder by crediting the account of the Holder's prime
 broker with the Depository Trust Company through its Deposit Withdrawal At
 Custodian ("DWAC") system if the Company is a participant in such system,
 and otherwise by physical delivery to the address specified by the Holder
 in the Notice of Exercise within three Business Days from the delivery to
 the Company of the Notice of Exercise Form, surrender of this Warrant and
 payment of the aggregate Exercise Price as set forth above ("Warrant Share
 Delivery Date").  This Warrant shall be deemed to have been exercised on the
 date the Exercise Price is received by the Company. The Warrant Shares shall
 be deemed to have been issued, and Holder or any other person so designated
 to be named therein shall be deemed to have become a holder of record of
 such shares for all purposes, as of the date the Warrant has been exercised
 by payment to the Company of the Exercise Price and all taxes required to
 be paid by the Holder, if any, pursuant to Section 2(c)(v) prior to the
 issuance of such shares, have been paid.

                (iii)  Delivery of New Warrants Upon Exercise.  If this
 Warrant shall have been exercised in part, the Company shall, at the time
 of delivery of the certificate or certificates representing Warrant Shares,
 deliver to Holder a new Warrant evidencing the rights of Holder to purchase
 the unpurchased Warrant Shares called for by this Warrant, which new Warrant
 shall in all other respects be identical with this Warrant.

                (iv)  No Fractional Shares or Scrip. No fractional shares or
 scrip representing fractional shares shall be issued upon the exercise of
 this Warrant. As to any fraction of a share which Holder would otherwise
 be entitled to purchase upon such exercise, the Company shall pay a cash
 adjustment in respect of such final fraction in an amount equal to such
 fraction multiplied by the Exercise Price.

                (v) Charges, Taxes and Expenses. Issuance of certificates for
 Warrant Shares shall be made without charge to the Holder for any issue or
 transfer tax or other incidental expense in respect of the issuance of such
 certificate, all of which taxes and expenses shall be paid by the Company,
 and such certificates shall be issued in the name of the Holder or in such
 name or names as may be directed by the Holder; provided, however, that in
 the event certificates for Warrant Shares are to be issued in a name other
 than the name of the Holder, this Warrant when surrendered for exercise
 shall be accompanied by the Assignment Form attached hereto duly executed by
 the Holder; and the Company may require, as a condition thereto, the payment
 of a sum sufficient to reimburse it for any transfer tax incidental thereto.

                (vi)  Closing of Books. The Company will not close its
 stockholder books or records in any manner which prevents the timely
 exercise of this Warrant, pursuant to the terms hereof.

      Section 3. Certain Adjustments.

           (a) Stock Dividends and Splits. If the Company, at any time while
 this Warrant is outstanding: (A) pays a stock dividend or otherwise make a
 distribution or distributions on shares of its Common Stock or any other
 equity or equity equivalent securities payable in shares of Common Stock,
 (B) subdivides outstanding shares of Common Stock into a larger number of
 shares, (C) combines (including by way of reverse stock split) outstanding
 shares of Common Stock into a smaller number of shares, or (D) issues by
 reclassification of shares of the Common Stock any shares of capital stock
 of the Company, then in each case the Exercise Price shall be multiplied by
 a fraction of which the numerator shall be the number of shares of Common
 Stock (excluding treasury shares, if any) outstanding immediately before
 such event and of which the denominator shall be the number of shares of
 Common Stock outstanding immediately after such event and the number of
 shares issuable upon exercise of this Warrant shall be proportionately
 adjusted. Any adjustment made pursuant to this Section 3(a) shall become
 effective immediately upon the date and time a dividend or distribution is
 made or after the effective date in the case of a subdivision, combination
 or reclassification.

           (b) Pro Rata Distributions.  If the Company, at any time prior to
 the Termination Date, shall distribute to all holders of Common Stock (and
 not to Holders of the Warrants) evidences of its indebtedness or assets
 (including cash and cash dividends) or rights or warrants to subscribe
 for or purchase any security other than the Common Stock (which shall be
 subject to Section 3(b)), then in each such case the Exercise Price shall
 be adjusted by multiplying the Exercise Price in effect immediately prior to
 the record date fixed for determination of stockholders entitled to receive
 such distribution by a fraction of which the denominator shall be the Market
 Price determined as of the record date mentioned above, and of which the
 numerator shall be such Market Price on such record date less the then per
 share fair market value at such record date of the portion of such assets or
 evidence of indebtedness so distributed applicable to one outstanding share
 of the Common Stock as determined by the Board of Directors in good faith.
 In either case the adjustments shall be described in a statement provided
 to the Holder of the portion of assets or evidences of indebtedness so
 distributed or such subscription rights applicable to one share of Common
 Stock. Such adjustment shall be made whenever any such distribution is made
 and shall become effective immediately after the record date mentioned
 above.

           (c) Calculations. All calculations under this Section 3 shall be
 made to the nearest cent or the nearest 1/100th of a share, as the case may
 be. For purposes of this Section 3, the number of shares of Common Stock
 deemed to be issued and outstanding as of a given date shall be the sum of
 the number of shares of Common Stock (excluding treasury shares, if any)
 issued and outstanding.

           (d) Other Equitable Adjustments.  Upon such events described in
 Section 3(a) and (b), all other items derived from the number of shares
 outstanding or the price of the Common Stock, including without limitation
 the Acceleration Period, shall be equitably adjusted,

           (e) Notice to Holders.

                (i) Adjustment to Exercise Price.  Whenever the Exercise
 Price is adjusted pursuant to this Section 3, the Company shall promptly
 mail to each Holder a notice setting forth the Exercise Price after such
 adjustment and setting forth a brief statement of the facts requiring such
 adjustment.

                (ii)  Notice to Allow Exercise by Holder. If (A) the Company
 shall declare a dividend (or any other distribution) on the Common Stock;
 (B) the Company shall declare a special nonrecurring cash dividend on or a
 redemption of the Common Stock; (C) the Company shall authorize the granting
 to all holders of the Common Stock rights or warrants to subscribe for or
 purchase any shares of capital stock of any class or of any rights; (D) the
 approval of any stockholders of the Company shall be required in connection
 with any reclassification of the Common Stock, any consolidation or
 merger to which the Company is a party, any sale or transfer of all or
 substantially all of the assets of the Company, of any compulsory share
 exchange whereby the Common Stock is converted into other securities, cash
 or property; (E) the Company's board of directors shall approve a tender
 or exchange offer for the Company's Common Stock or the Company receives
 written notice of a third party's intention to commence a tender offer for
 the Company's Common Stock; or (F) the Company shall authorize the voluntary
 or involuntary dissolution, liquidation or winding up of the affairs of the
 Company; then, in each case, the Company shall cause to be mailed to the
 Holder at its last address as it shall appear upon the Warrant Register of
 the Company, at least 20 calendar days prior to the applicable record or
 effective date hereinafter specified, a notice stating (1) the date on which
 a record is to be taken for the purpose of such dividend, distribution,
 redemption, rights or warrants, or if a record is not to be taken, the date
 as of which the holders of the Common Stock of record to be entitled to such
 dividend, distributions, redemption, rights or warrants are to be determined
 or (2) the date on which such reclassification, consolidation, merger, sale,
 transfer or share exchange is expected to become effective or close, and the
 date as of which it is expected that holders of the Common Stock of record
 shall be entitled to exchange their shares of the Common Stock for
 securities, cash or other property deliverable upon such reclassification,
 consolidation, merger, sale, transfer or share exchange; provided, that the
 failure to mail such notice or any defect therein or in the mailing thereof
 shall not affect the validity of the corporate action required to be
 specified in such notice. The Holder is entitled to exercise this Warrant
 during the 20-day period commencing on the date of such notice to the
 effective date of the event triggering such notice.

      Section 4. Transfer of Warrant.

           (a) Transferability. Subject to compliance with any applicable
 securities laws and the conditions set forth in Sections 5(a) and 4(c)
 hereof and to the provisions of Section 4.1 of the Purchase Agreement, this
 Warrant and all rights hereunder are transferable in whole upon surrender of
 this Warrant at the principal office of the Company, together with a written
 assignment of this Warrant substantially in the form attached hereto duly
 executed by the Holder or its agent or attorney and funds sufficient to pay
 any transfer taxes payable upon the making of such transfer. Upon such
 surrender and, if required, such payment, the Company shall execute and
 deliver a new Warrant or Warrants in the name of the assignee.

           (b) Warrant Register. The Company shall register this Warrant,
 upon records to be maintained by the Company for that purpose (the "Warrant
 Register"), in the name of the record Holder hereof from time to time. The
 Company may deem and treat the registered Holder of this Warrant as the
 absolute owner hereof for the purpose of any exercise hereof or any
 distribution to the Holder, and for all other purposes, absent actual
 notice to the contrary.

           (c) Transfer Restrictions.  The Company may require, as a
 condition of allowing a transfer of this Warrant that the Holder or
 transferee of this Warrant, as the case may be, furnish to the Company a
 written opinion of counsel (which opinion shall be in form, substance and
 scope customary for opinions of counsel in comparable transactions) to
 the effect that such transfer may be made without registration under the
 Securities Act and under applicable state securities or blue sky laws,
 (ii) that the holder or transferee execute and deliver to the Company an
 investment letter in form and substance acceptable to the Company, and
 (iii) that the transferee be an "accredited investor" as defined in
 Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the
 Securities Act or a qualified institutional buyer as defined in Rule 144A(a)
 under the Securities Act.

      Section 5. Miscellaneous.

           (a) Title to Warrant.  Prior to the Termination Date and subject
 to compliance with applicable laws and Section 4 of this Warrant, this
 Warrant and all rights hereunder are transferable, in whole or in part,
 at the office or agency of the Company by the Holder in person or by duly
 authorized attorney, upon surrender of this Warrant together with the
 Assignment Form annexed hereto properly endorsed. The transferee shall sign
 an investment letter in form and substance reasonably satisfactory to the
 Company.

           (b) No Rights as Shareholder Until Exercise.  This Warrant does
 not entitle the Holder to any voting rights or other rights as a shareholder
 of the Company prior to the exercise hereof. Upon the surrender of this
 Warrant and the payment of the aggregate Exercise Price, the Warrant Shares
 so purchased shall be and be deemed to be issued to such Holder as the
 record owner of such shares as of the close of business on the later of
 the date of such surrender or payment.

           (c) Loss, Theft, Destruction or Mutilation of Warrant.  The
 Company covenants that upon receipt by the Company of evidence reasonably
 satisfactory to it of the loss, theft, destruction or mutilation of this
 Warrant or any stock certificate relating to the Warrant Shares, and in
 case of loss, theft or destruction, of indemnity or security reasonably
 satisfactory to it (which, in the case of the Warrant, shall not include the
 posting of any bond), and upon surrender and cancellation of such Warrant or
 stock certificate, if mutilated, the Company will make and deliver a new
 Warrant or stock certificate of like tenor and dated as of such
 cancellation, in lieu of such Warrant or stock certificate.

           (d) Saturdays, Sundays, Holidays, etc. If the last or appointed
 day for the taking of any action or the expiration of any right required
 or granted herein shall be a Saturday, Sunday or a legal holiday, then such
 action may be taken or such right may be exercised on the next succeeding
 day not a Saturday, Sunday or legal holiday.

           (e) Jurisdiction.  All questions concerning the construction,
 validity, enforcement and interpretation of this Warrant shall be determined
 in accordance with the provisions of the Purchase Agreement.

           (f) Restrictions.  The Holder acknowledges that the Warrant Shares
 acquired upon the exercise of this Warrant, if not registered, will have
 restrictions upon resale imposed by state and federal securities laws.

           (g) Nonwaiver and Expenses.  No course of dealing or any delay or
 failure to exercise any right hereunder on the part of Holder or the Company
 shall operate as a waiver of such right or otherwise prejudice Holder's or
 the Company's respective rights, powers or remedies.

           (h) Notices.  Any notice, request or other document required or
 permitted to be given or delivered to the Holder by the Company shall be
 delivered in accordance with the notice provisions of the Purchase
 Agreement.

           (i) Successors and Assigns.  Subject to applicable securities
 laws, this Warrant and the rights and obligations evidenced hereby shall
 inure to the benefit of and be binding upon the successors of the Company
 and the successors and permitted assigns of Holder. The provisions of this
 Warrant are intended to be for the benefit of all Holders from time to time
 of this Warrant and shall be enforceable by any such Holder or holder of
 Warrant Shares.

           (j) Amendment.  This Warrant may be modified or amended or the
 provisions hereof waived with the written consent of the Company and the
 Holder.

           (k) Severability.  Wherever possible, each provision of this
 Warrant shall be interpreted in such manner as to be effective and valid
 under applicable law, but if any provision of this Warrant shall be
 prohibited by or invalid under applicable law, such provision shall be
 ineffective to the extent of such prohibition or invalidity, without
 invalidating the remainder of such provisions or the remaining provisions
 of this Warrant.

           (l) Headings. The headings used in this Warrant are for the
 convenience of reference only and shall not, for any purpose, be deemed a
 part of this Warrant.

      IN WITNESS WHEREOF, the Company has caused this Warrant to be executed
 by its officer thereunto duly authorized.

 Dated: November 18, 2005

                                    CARRINGTON LABORATORIES, INC.

                                    By:
                                    -----------------------------
                                    Name: Carlton E. Turner
                                    Title: President & CEO

<PAGE>

                              NOTICE OF EXERCISE

 TO:  CARRINGTON LABORATORIES, INC.

      (1) The undersigned hereby elects to purchase _______ Warrant Shares of
 the Company pursuant to the terms of the attached Warrant (only if exercised
 in full),  and  tenders  herewith  payment  of the exercise price  in  full,
 together with all applicable transfer taxes, if any.

      (2)  Please issue  a  certificate  or  certificates  representing  said
 Warrant Shares in the name of the undersigned  or  in such other name as  is
 specified below:

                           ________________________

      The Warrant Shares shall be delivered to the following:

                           ________________________
                           ________________________
                           ________________________

      (3) Accredited Investor.  The undersigned is an "accredited  investor"
 as defined in Regulation D promulgated under the Securities Act of 1933, as
 amended.

 [SIGNATURE OF HOLDER]
 (for entities)

 Name of Investing Entity:
                           -------------------------------------------------
 Signature of Authorized Signatory of Investing Entity:
                                                       ---------------------
 Name of Authorized Signatory:
                               ---------------------------------------------
 Title of Authorized Signatory:
                                --------------------------------------------
 Date:
       ---------------------------------------------------------------------

 (for individuals)

 Signature:
            ----------------------------------------------------------------
 Name:
       ---------------------------------------------------------------------
 Date:
       ---------------------------------------------------------------------

<PAGE>

                               ASSIGNMENT FORM

   (To assign the foregoing warrant, execute this form and supply required
                                 information.
                Do not use this form to exercise the warrant.)

 FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby
 are hereby assigned to _________________ (the "Assignee") whose address is

 --------------------------------------------------------------------------

 --------------------------------------------------------------------------

                          Dated:
                                 ------------------------------------------
                          Holder's Signature:
                                              -----------------------------
                          Holder's Address:
                                            -------------------------------

 The Assignee agrees  that it shall  hereinafter be subject  to the terms  of
 Sections 4.1 and 4.2 of the Purchase  Agreement to the same extent that  the
 prior Holder  was subject  to such  terms  prior to  the assignment  of  the
 Warrants.

                          Dated:
                                 ------------------------------------------
                          Assignees Signature:
                                               ----------------------------
                          Assignees Address:
                                             ------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]